The Pharma Services & Active Ingredients business of Dr. Reddy’s serves Generics and Innovator companies through the Active Pharmaceutical Ingredients (API) and Custom Pharmaceutical Services (CPS) businesses respectively.
Dr. Reddy’s began API operations in 1984 and started with a single drug in a 60-tonne facility near Hyderabad, India. In 1986, the first consignment of that drug, Methyldopa, was shipped to West Germany. Strong Chemistry skills and our emphasis on high quality led to USFDA inspections of our manufacturing facilities. Since then, Dr. Reddy’s has come a long way and today has a wide portfolio of APIs.
Our core strength in APIs has continued to increase significantly over the years. We have the largest number of US DMF submissions from India and are among the top three API players globally. Our Global API business offers over 100 molecules to customers across the world.
Our CPS business, formed in 2001, serves more than five big pharmaceutical companies and over 25 emerging pharma companies today. The CPS business got a boost in 2005 with the acquisition of Roche’s API manufacturing unit in Mexico. This facility added a niche capability of steroid API manufacture to our capability portfolio. In 2008, with the acquisition of the Small Molecule business of Dow Pharma at its Mirfield and Cambridge sites, UK, CPS business got stronger in its service offerings. Today, we are the largest CPS player from India. Our CPS business provides a unique opportunity for Innovator companies worldwide to make use of our technical expertise, world-class infrastructure, and flexibility to bring their medicines to the market quickly and economically.
Dr. Reddy’s has emerged as a trusted supplier of value-added advanced intermediates and APIs to generic as well as innovator companies. A spate of new launches, development of a varied pipeline, addition of new capacities and product lines (Oncology, Hormones), and the expansion of our marketing and regulatory teams have set the tone for robust growth. As one of the few integrated pharma companies to provide Custom Pharmaceutical Services, we are also emerging as a 'partner of choice' for innovator companies globally.
